In short
This article explores the use of Poloxamer 407 (also known as Poloxamer 188) in clinical trials for the treatment of sickle cell disease. Poloxamer 407 is being investigated as a potential therapy to reduce the duration and severity of painful vaso-occlusive crises in patients with sickle cell anemia. The trials aim to assess the efficacy, safety, and impact on pain management and hospitalization duration for patients experiencing these crises.
At a glance
- Drug Name
- Poloxamer 407 (also known as Poloxamer 188)
- Condition Studied
- Sickle Cell Anemia
- Trial Phase
- Phase III
- Study Design
- Randomized, double-blind, placebo-controlled, multicenter
- Primary Objective
- Assess efficacy in reducing duration of painful vaso-occlusive crisis
- Secondary Objectives
- Evaluate effects on pain intensity, analgesic use, and hospitalization length
- Treatment Duration
- 48-hour continuous infusion
- Follow-up Period
- Days 7-14 and 28-35 after treatment
- Patient Stratification
- Based on hydroxyurea use
- Treatment Initiation
- Within 12 hours of crisis presentation
What is Poloxamer 407?
Poloxamer 407, also known as Poloxamer 188, is a drug that has shown promise in treating sickle cell disease, a genetic blood disorder that affects millions of people worldwide. This medication is being studied to help patients who experience painful episodes called vaso-occlusive crises, which are a hallmark of sickle cell disease.
How Does It Work?
While the exact mechanism is not fully explained in the provided information, Poloxamer 407 is believed to help reduce the duration and severity of painful vaso-occlusive crises in sickle cell disease patients. These crises occur when abnormally shaped red blood cells block small blood vessels, causing pain and potential organ damage.
Treating Sickle Cell Disease
Sickle cell disease is a condition where red blood cells become crescent or "sickle" shaped, leading to various complications. Poloxamer 407 is being investigated as a treatment specifically for the painful episodes associated with this disease. The goal is to provide relief to patients during these crises and potentially reduce the need for other pain medications.
Clinical Trial Details
A Phase III clinical trial (NCT00004408) was conducted to assess the effectiveness of Poloxamer 407 in treating sickle cell disease. Here are some key details about the study:
- Study Type: The trial was randomized, double-blind, and placebo-controlled. This means that participants were randomly assigned to receive either Poloxamer 407 or a placebo (a substance with no active ingredients), and neither the patients nor the researchers knew who received which treatment during the study.
- Administration: Poloxamer 407 was given to patients through continuous infusion (a steady flow into the bloodstream) for 48 hours when they presented with a vaso-occlusive crisis.
- Timing: Treatment began within 12 hours of a patient experiencing a crisis.
- Assessment: Pain levels were evaluated before, during, and after the treatment to determine the drug's effectiveness.
- Follow-up: Patients were monitored on days 7-14 and 28-35 after treatment to assess any long-term effects or benefits.
Potential Benefits
The clinical trial aimed to determine if Poloxamer 407 could provide the following benefits for sickle cell disease patients:
- Reduced Crisis Duration: The primary goal was to shorten the length of painful vaso-occlusive crises.
- Pain Relief: Researchers assessed whether the drug could decrease both the duration and intensity of pain during crises.
- Less Need for Pain Medication: The study looked at whether Poloxamer 407 could reduce the total amount of pain medication (analgesics) needed during a crisis.
- Shorter Hospital Stays: Another potential benefit being investigated was whether the treatment could lead to shorter periods of hospitalization for patients experiencing crises.
It's important to note that while these potential benefits were being studied, the results of the trial are not provided in the given information. Patients interested in this treatment should consult with their healthcare providers for the most up-to-date information on Poloxamer 407 and its effectiveness in treating sickle cell disease.